Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia

Wake Forest University8 enrolled

Overview

The purpose of this research study is to see if a specific protein that we are interested in is involved in scarring hair loss. If these proteins are involved, further genetic work may also better define the disease as well as future treatment options.

This is a single-center study, designed to evaluate the expression of Fas protein in skin biopsies of patients with scarring alopecia including fourteen patients with central centrifugal scarring alopecia (CCSA), three patients with lichen planopilaris (LP) and three patients with discoid lupus erythematosus (DLE). Skin biopsies of five healthy participants will be used as controls.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Central Centrifugal Scarring Alopecia Lichen Planopilaris Discoid Lupus Erythematosus

Eligibility

Sex: FEMALEMin age: 30 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Participants ages 30 years or older with a biopsy- proven diagnosis of CCSA. * Undergone standard of care treatment for CCSA by a WFUSM Dermatologist * Women of child bearing age will be required to have a negative pregnancy test in order to participate in the study * Participants ages 30 years or older with a biopsy- proven diagnosis of LP. * Participants ages 30 years or older with a biopsy- proven diagnosis of DLE. * Healthy participants must be ages 30 years or older. Exclusion Criteria: * Age less than 30 years of age. * Clinically evident bacterial or viral infection of the scalp. * Pregnant or nursing woman of child-bearing potential. * Participation in any other investigative research study involving study medication. * Inability to return for the biopsy visit.

Locations (1)

Wake Forest University Health Sciences Dermatology

Winston-Salem, North Carolina, United States

Outcomes

Primary Outcomes

To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia (CCSA), lichen planopilaris (LP) and discoid lupus erythematosus (DLE) and in healthy controls.

Time frame: 8 weeks

Secondary Outcomes

To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia before and after treatment with intralesional and topical steroids.

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.